Corporate Symposia
Corporate Lunch Symposium 1: Eisai
Brain tumour related epilepsy: what is the evidence for targeting the AMPA glutamate receptor?
This promotional symposium has been organised and funded by Eisai Europe Ltd. This meeting is intended for HCPs. The content is aligned with EU and UK marketing authorisations and approved according to ABPI and EFPIA codes.
EMEA-PER-21-00081 | August 2021
Saturday, September 25, 12:30 - 13:30 hrs
Chair: Dr Gilles Huberfeld (Paris, FR)
| 12:30 – 12:35 | Welcome and Introductions |
Dr Gilles Huberfeld, Neurologist, Hospital Foundation Adolphe De Rothschild, France | |
| 12:35 – 12:50 | Pathogenesis of brain tumour related epilepsy (BTRE): what is the role of the glutamatergic system? |
Dr Gilles Huberfeld, Neurologist, Hospital Foundation Adolphe De Rothschild, France | |
| 12:50 – 13:05 | Targeting the AMPA glutamate receptor for BTRE |
Dr Antonietta Coppola, Assistant Professor of Neurology, University of Naples Federico II, Italy | |
| 13:05 – 13:20 | Quality of life in patients with BTRE: looking beyond seizure control |
Dr Katherine Peters, Associate Professor of Neurology and Neurosurgery, Preston Robert Tisch Brain Tumor Center, Duke University, USA | |
| 13:20 – 13:30 | Q&A/Discussion |
All |
Seizures are among the most common symptoms of brain tumours and can have a substantial impact on the daily lives of patients. The mechanism of epileptogenesis is not completely understood but is believed to be multifactorial, with evidence identifying glutamate as one of the key drivers for brain tumour related epilepsy (BTRE). Proposed mechanisms of seizure generation in patients with BTRE will be outlined; and data for this patient population from a prospective,multicentre observational study using an antiseizure medication (ASM), which targets the glutamate AMPA receptor, will be presented. Furthermore, the quality of life in BTRE patients will be discussed and how an individualised approach is required for choosing an ASM to help maintain good seizure control without increasing the overall burden to patients and their families.
Corporate Lunch Symposium 2: AstraZeneca
Evolving landscape in the treatment of plexiform neurofibromas associated with NF1
This promotional satellite symposium is intended for healthcare professionals and is organised and funded by AstraZeneca Veeva ID: Z4-36912
Date of Preparation: September 2021
Saturday, September 25, 12:30 - 13:30 hrs
Chair: Amedeo Azizi, (Austria)
| 12:30 – 12:40 | Unmet clinical need and burden of disease in NF1 |
Amedeo Azizi, Austria | |
| 12:40 – 13:00 | The treatment landscape of NF1-PNs |
Darren Hargraves, United Kingdom | |
| 13:00 – 13:20 | NF1-PN clinical cases |
João Passos, Portugal | |
| 13:20 – 13:30 | Live Audience Q&A |
Plexiform neurofibromas (PNs) present in 30-50% of patients with neurofibromatosis type 1 (NF1). PNs typically manifest early, developing rapidly in early childhood and have the potential to cause significant pain, disability, and disfigurement, depending on their location and size.
Historically, the only treatment for PNs was surgery, but some are difficult to fully resect due to tissue infiltration and hypervascularisation. MEK inhibitors, such as selumetinib, have been investigated as a therapeutic option for the treatment of inoperable NF1-PNs.
This symposium will discuss the current treatment landscape for NF1-PNs, including data from the Phase II SPRINT clinical trial, evaluating selumetinib for the treatment of symptomatic, inoperable NF1-PN in children and adolescents, and case studies from early access programs, showing use of selumetinib in clinical practice.
Link to Koselugo▼ (selumetinib) EU prescribing information: https://bit.ly/3DLfqQX
